AbbVie Inc. (NYSE:ABBV) reported fourth-quarter 2025 sales of $16.62 billion on Wednesday, beating the consensus of $16.42 billion.
Sales increased 10% on a reported basis or 9.5% on an operational basis. The company reported adjusted earnings of $2.71 per share, up 25.5%, beating the consensus of $2.65.
Global net revenues from the immunology portfolio were $8.63 billion, up 18.3% (+17.7% on an operational basis), including Skyrizi sales increased 32.5% to $5.01 billion; Rinvoq sales reached $2.37 billion, an increase of 29.5%; and Humira sales fell 25.9% to $1.25 billion.
Neuroscience portfolio …